An association that did not reach statistical significance was observed between clinical response and an increase in sAXL ( P = 0.08), a soluble form of AXL that negatively regulates ALX signaling by binding to GAS6. 55 Some preclinical studies in NF1-deficient malignant peripheral nerve sheath tumors suggest that combination strategies of MEK inhibitors with MET or SHP2 inhibitors may overcome tumor resistance.
← all excerpts
Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review.
1
0.0800
0.0800